Loading...
    Loading...
    LEADERBOARD
labroots
Login here
Register Free
  • LOGIN
  • REGISTER FREE
Login here
Register Free
Follow

Orthotopic Models

Orthotopic models are generated by inoculating tumor cell lines into the anatomically corresponding tissue in an animal model, for example, seeding a breast cancer cell line into the mammary fat pad of a mouse. This type of model is beneficial to translational research as the tumor can be evaluated in a highly relevant environment and it closely mimics human disease.

Webinars

  • MAY 16, 2023 | 8:00 AM
    Multivalent RNA CAR-T cell for malignant glioma
    Multivalent RNA CAR-T cell for malignant glioma
    The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
    Speaker: Prof. Denis Migliorini
    Sponsored By: MaxCyte®
    13
    JUN 02, 2021 | 12:00 AM
    Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
    Interrogating mechanisms of tumor-specific T cell exhaustion and...
    Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
    Speaker: Adam Burrack, M.S., Ph.D.
    Presented at: Immuno-Oncology Virtual Event Series 2021
    3
    JUN 02, 2021 | 12:00 AM
    Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
    Development of FGFR4 targeted Chimeric Antigen Receptors (CARs)...
    Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
    Speaker: Peter Sullivan, PhD
    Presented at: Immuno-Oncology Virtual Event Series 2021
    1
MAY 16, 2023 | 8:00 AM
Multivalent RNA CAR-T cell for malignant glioma
Multivalent RNA CAR-T cell for malignant glioma
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Speaker: Prof. Denis Migliorini
Sponsored By: MaxCyte®
13
JUN 02, 2021 | 12:00 AM
Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma
Interrogating mechanisms of tumor-specific T cell exhaustion and...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Speaker: Adam Burrack, M.S., Ph.D.
Presented at: Immuno-Oncology Virtual Event Series 2021
3
JUN 02, 2021 | 12:00 AM
Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma
Development of FGFR4 targeted Chimeric Antigen Receptors (CARs)...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Speaker: Peter Sullivan, PhD
Presented at: Immuno-Oncology Virtual Event Series 2021
1
Let's Talk Science. Let's Talk Medicine.

The leading scientific social networking website and producer of educational virtual events and webinars.

About Us The Team Contact Us Careers Media Kit Virtual Events Posters Multimedia Blog Press Room Science Store Gift Card Balance
Continuing Education Scholarships Leaderboard Order Policy Shipping Policy Privacy Policy Terms and Conditions User Agreement User Data Request Copyrights Support Chati
© 2008-2025 Labroots Inc.
Opens in a new window Opens an external site Opens an external site in a new window
Modal title